Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $64 to $68.